JP2008535821A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008535821A5 JP2008535821A5 JP2008503236A JP2008503236A JP2008535821A5 JP 2008535821 A5 JP2008535821 A5 JP 2008535821A5 JP 2008503236 A JP2008503236 A JP 2008503236A JP 2008503236 A JP2008503236 A JP 2008503236A JP 2008535821 A5 JP2008535821 A5 JP 2008535821A5
- Authority
- JP
- Japan
- Prior art keywords
- antagonist
- met
- exon
- stabilized
- over
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000005557 antagonist Substances 0.000 claims 17
- 229920001184 polypeptide Polymers 0.000 claims 6
- 102000004196 processed proteins & peptides Human genes 0.000 claims 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 230000007781 signaling event Effects 0.000 claims 3
- 102000008022 Proto-Oncogene Proteins c-met Human genes 0.000 claims 1
- 108010089836 Proto-Oncogene Proteins c-met Proteins 0.000 claims 1
- 230000015556 catabolic process Effects 0.000 claims 1
- 230000006800 cellular catabolic process Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000006731 degradation reaction Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 230000017854 proteolysis Effects 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 230000001629 suppression Effects 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US66548205P | 2005-03-25 | 2005-03-25 | |
| PCT/US2006/010850 WO2006104911A2 (en) | 2005-03-25 | 2006-03-24 | Methods and compositions for modulating hyperstabilized c-met |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012116934A Division JP2012232979A (ja) | 2005-03-25 | 2012-05-22 | 過剰に安定化したｃ−ｍｅｔを調節するための方法及び組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008535821A JP2008535821A (ja) | 2008-09-04 |
| JP2008535821A5 true JP2008535821A5 (enExample) | 2009-04-09 |
Family
ID=37053941
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008503236A Pending JP2008535821A (ja) | 2005-03-25 | 2006-03-24 | 過剰に安定化したｃ−ｍｅｔを調節するための方法及び組成物 |
| JP2012116934A Pending JP2012232979A (ja) | 2005-03-25 | 2012-05-22 | 過剰に安定化したｃ−ｍｅｔを調節するための方法及び組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012116934A Pending JP2012232979A (ja) | 2005-03-25 | 2012-05-22 | 過剰に安定化したｃ−ｍｅｔを調節するための方法及び組成物 |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US7615529B2 (enExample) |
| EP (1) | EP1868648B1 (enExample) |
| JP (2) | JP2008535821A (enExample) |
| KR (1) | KR20080000613A (enExample) |
| CN (1) | CN101184506B (enExample) |
| AU (1) | AU2006229989B2 (enExample) |
| BR (1) | BRPI0611468A2 (enExample) |
| CA (1) | CA2599988A1 (enExample) |
| ES (1) | ES2539790T3 (enExample) |
| IL (1) | IL185708A (enExample) |
| MX (1) | MX2007011652A (enExample) |
| NO (1) | NO20075412L (enExample) |
| NZ (1) | NZ561211A (enExample) |
| RU (1) | RU2404193C2 (enExample) |
| SG (1) | SG159547A1 (enExample) |
| WO (1) | WO2006104911A2 (enExample) |
| ZA (1) | ZA200707953B (enExample) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1868648B1 (en) * | 2005-03-25 | 2015-04-15 | Genentech, Inc. | Methods and compositions for modulating hyperstabilized c-met |
| JP2011513427A (ja) * | 2008-03-06 | 2011-04-28 | ジェネンテック， インコーポレイテッド | ｃ−ｍｅｔ及びＥＧＦＲアンタゴニストの併用療法 |
| BRPI0919840B1 (pt) * | 2008-10-01 | 2023-02-28 | Amgen Research (Munich) Gmbh | Molécula de anticorpo de cadeia única biespecífica, seu uso, e composição farmacêutica que a compreende |
| PA8849001A1 (es) | 2008-11-21 | 2010-06-28 | Lilly Co Eli | Anticuerpos de c-met |
| MX2011010158A (es) * | 2009-04-07 | 2011-10-17 | Roche Glycart Ag | Anticuerpos biespecificos anti-erbb-2/anti-c-met. |
| AU2010233994A1 (en) | 2009-04-07 | 2011-09-22 | Roche Glycart Ag | Bispecific anti-ErbB-3/anti-c-Met antibodies |
| US9181339B2 (en) | 2009-04-20 | 2015-11-10 | Oxford Bio Therapeutics Ltd. | Antibodies specific to cadherin-17 |
| KR101671378B1 (ko) * | 2009-10-30 | 2016-11-01 | 삼성전자 주식회사 | ｃ-Ｍｅｔ에 특이적으로 결합하는 항체 및 그의 용도 |
| TWI600760B (zh) | 2009-11-05 | 2017-10-01 | 建南德克公司 | 分泌異源多肽之方法及組合物 |
| RS66008B1 (sr) | 2010-03-10 | 2024-10-31 | Genmab As | Monoklonska antitela protiv c-met |
| US20130259878A1 (en) * | 2010-10-20 | 2013-10-03 | Oxford Biotherapeutics Ltd | Antibodies |
| AU2012275233A1 (en) | 2011-06-30 | 2013-11-28 | Genentech, Inc. | Anti-c-met antibody formulations |
| WO2013033008A2 (en) | 2011-08-26 | 2013-03-07 | Merrimack Pharmaceuticals, Inc. | Tandem fc bispecific antibodies |
| US9201074B2 (en) | 2011-09-20 | 2015-12-01 | Eli Lilly And Company | Anti-c-Met antibodies |
| WO2013049112A1 (en) * | 2011-09-27 | 2013-04-04 | Emory University | Detection of biomarkers using magnetic resonance |
| KR20130036993A (ko) | 2011-10-05 | 2013-04-15 | 삼성전자주식회사 | ｃ-Ｍｅｔ의 ＳＥＭＡ 도메인 내의 에피토프에 특이적으로 결합하는 항체 |
| AU2012340826A1 (en) * | 2011-11-21 | 2014-05-29 | Genentech, Inc. | Purification of anti-c-met antibodies |
| US9931400B2 (en) | 2012-09-12 | 2018-04-03 | Samsung Electronics Co., Ltd. | Method of combination therapy for prevention or treatment of c-Met or angiogenesis factor induced diseases |
| HUE045435T2 (hu) | 2012-10-12 | 2019-12-30 | Medimmune Ltd | Pirrolobenzodiazepinek és konjugátumaik |
| US10260089B2 (en) | 2012-10-29 | 2019-04-16 | The Research Foundation Of The State University Of New York | Compositions and methods for recognition of RNA using triple helical peptide nucleic acids |
| EP2914629A1 (en) | 2012-11-05 | 2015-09-09 | MAB Discovery GmbH | Method for the production of multispecific antibodies |
| EP2727941A1 (en) | 2012-11-05 | 2014-05-07 | MAB Discovery GmbH | Method for the production of multispecific antibodies |
| MX2015011712A (es) | 2013-03-06 | 2016-04-04 | Merrimack Pharmaceuticals Inc | Anticerpos biespecificos fc en fila anti-c-met. |
| JP6444902B2 (ja) | 2013-03-13 | 2018-12-26 | メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ | ピロロベンゾジアゼピン及びその結合体 |
| US9168300B2 (en) | 2013-03-14 | 2015-10-27 | Oncomed Pharmaceuticals, Inc. | MET-binding agents and uses thereof |
| US9567641B2 (en) * | 2013-07-03 | 2017-02-14 | Samsung Electronics Co., Ltd. | Combination therapy for the treatment of cancer using an anti-C-met antibody |
| JP6464166B2 (ja) | 2013-11-14 | 2019-02-06 | エンドサイト・インコーポレイテッドＥｎｄｏｃｙｔｅ， Ｉｎｃ． | 陽電子放出断層撮影用の化合物 |
| WO2015139046A1 (en) | 2014-03-14 | 2015-09-17 | Genentech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| EP3122900A1 (en) | 2014-03-24 | 2017-02-01 | F. Hoffmann-La Roche AG | Cancer treatment with c-met antagonists and correlation of the latter with hgf expression |
| JP6531166B2 (ja) | 2014-09-10 | 2019-06-12 | メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ | ピロロベンゾジアゼピン及びそのコンジュゲート |
| WO2016042412A1 (en) | 2014-09-16 | 2016-03-24 | Symphogen A/S | Anti-met antibodies and compositions |
| GB201419108D0 (en) * | 2014-10-27 | 2014-12-10 | Glythera Ltd | Materials and methods relating to linkers for use in antibody drug conjugates |
| US20180057595A1 (en) | 2015-03-16 | 2018-03-01 | Celldex Therapeutics, Inc. | Anti-MET Antibodies and Methods of Use Thereof |
| ES2837755T3 (es) | 2016-09-14 | 2021-07-01 | Abbvie Biotherapeutics Inc | Anticuerpos anti-PD-1 |
| JP2019534882A (ja) | 2016-10-11 | 2019-12-05 | メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ | 免疫介在性療法薬を有する抗体−薬物コンジュゲート |
| TWI782930B (zh) | 2016-11-16 | 2022-11-11 | 美商再生元醫藥公司 | 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法 |
| CA3097381A1 (en) | 2018-04-17 | 2019-10-24 | Endocyte, Inc. | Methods of treating cancer |
| CA3098103A1 (en) | 2018-05-23 | 2019-11-28 | Adc Therapeutics Sa | Molecular adjuvant |
| BR112021000620A2 (pt) | 2018-07-15 | 2021-04-20 | Enochian BioPharma, Inc. | métodos e composições com uso de células dendríticas recombinantes para terapia contra câncer |
| US11459391B2 (en) | 2019-02-26 | 2022-10-04 | Janssen Biotech, Inc. | Combination therapies and patient stratification with bispecific anti-EGFR/c-Met antibodies |
| JOP20210304A1 (ar) | 2019-05-14 | 2023-01-30 | Janssen Biotech Inc | علاجات مركبة باستخدام الأجسام المضادة ثنائية النوعية المضادة لمستقبل عامل نمو البشرة (EGFR)/ مستقبل عامل نمو خلايا الكبد (c-Met) ومثبطات كيناز التيروسين الخاصة بمستقبل عامل نمو البشرة (EGFR) من الجيل الثالث |
| CN120097930A (zh) | 2019-05-20 | 2025-06-06 | 因多塞特股份有限公司 | 制备psma缀合物的方法 |
| KR20220063185A (ko) | 2019-09-16 | 2022-05-17 | 리제너론 파마슈티칼스 인코포레이티드 | 면역-pet 영상화를 위한 방사성 표지된 met 결합 단백질 |
| JOP20220184A1 (ar) | 2020-02-12 | 2023-01-30 | Janssen Biotech Inc | علاج مصابي السرطان ممن لديهم طفرات تخطي c-Met إكسون14 |
| WO2022079211A1 (en) | 2020-10-16 | 2022-04-21 | Adc Therapeutics Sa | Glycoconjugates |
| CN114478788B (zh) | 2020-11-11 | 2025-07-18 | 北京免疫方舟医药科技有限公司 | 一种同时靶向cd3和cd137的融合蛋白及其制备方法和用途 |
| GB202102396D0 (en) | 2021-02-19 | 2021-04-07 | Adc Therapeutics Sa | Molecular adjuvant |
| CA3236930A1 (en) | 2021-11-03 | 2022-04-21 | Hangzhou Dac Biotech Co., Ltd. | Specific conjugation of an antibody |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5686292A (en) * | 1995-06-02 | 1997-11-11 | Genentech, Inc. | Hepatocyte growth factor receptor antagonist antibodies and uses thereof |
| EP2014772A3 (en) | 1996-04-05 | 2009-05-27 | Antonio Giordano | Method for the diagnosis and prognosis of cancer |
| DE69739856D1 (de) | 1996-07-03 | 2010-06-02 | Genentech Inc | Agonisten für den rezeptor des hepatozyten-wachstumsfaktors und deren anwendungen |
| DE19651443A1 (de) * | 1996-12-11 | 1998-06-18 | Hoechst Ag | Selbstverstärkende, pharmakologisch kontrollierbare Expressionssysteme |
| NZ535925A (en) | 2002-04-16 | 2008-06-30 | Genentech Inc | An isolated antibody that binds to a particular polypeptide |
| BRPI0407446A (pt) * | 2003-02-13 | 2006-01-31 | Pharmacia Corp | Anticorpos para c-met para o tratamento de cânceres |
| EP2367008A3 (en) * | 2003-06-06 | 2014-12-24 | Genentech, Inc. | Modulating the interaction between HGF beta chain and C-Met |
| HN2004000285A (es) * | 2003-08-04 | 2006-04-27 | Pfizer Prod Inc | ANTICUERPOS DIRIGIDOS A c-MET |
| RU2006124743A (ru) * | 2003-12-11 | 2008-01-20 | Дженентек, Инк. (Us) | СПОСОБЫ И КОМПОЗИЦИИ ДЛЯ ИНГИБИРОВАНИЯ ДИМЕРИЗАЦИИ И АКТИВАЦИИ с-Мет |
| WO2005063816A2 (en) * | 2003-12-19 | 2005-07-14 | Genentech, Inc. | Monovalent antibody fragments useful as therapeutics |
| EP1868648B1 (en) | 2005-03-25 | 2015-04-15 | Genentech, Inc. | Methods and compositions for modulating hyperstabilized c-met |
| RU2007139516A (ru) | 2005-03-25 | 2009-04-27 | Дженентек, Инк. (Us) | Мутации с-мет при раке легких |
-
2006
- 2006-03-24 EP EP06748671.2A patent/EP1868648B1/en active Active
- 2006-03-24 CA CA002599988A patent/CA2599988A1/en not_active Abandoned
- 2006-03-24 ES ES06748671.2T patent/ES2539790T3/es active Active
- 2006-03-24 SG SG201000940-5A patent/SG159547A1/en unknown
- 2006-03-24 NZ NZ561211A patent/NZ561211A/en unknown
- 2006-03-24 JP JP2008503236A patent/JP2008535821A/ja active Pending
- 2006-03-24 AU AU2006229989A patent/AU2006229989B2/en active Active
- 2006-03-24 MX MX2007011652A patent/MX2007011652A/es active IP Right Grant
- 2006-03-24 KR KR1020077024503A patent/KR20080000613A/ko not_active Ceased
- 2006-03-24 BR BRPI0611468-7A patent/BRPI0611468A2/pt not_active Application Discontinuation
- 2006-03-24 US US11/388,757 patent/US7615529B2/en active Active
- 2006-03-24 CN CN2006800183951A patent/CN101184506B/zh active Active
- 2006-03-24 ZA ZA200707953A patent/ZA200707953B/xx unknown
- 2006-03-24 RU RU2007139452/10A patent/RU2404193C2/ru active
- 2006-03-24 WO PCT/US2006/010850 patent/WO2006104911A2/en not_active Ceased
-
2007
- 2007-09-04 IL IL185708A patent/IL185708A/en active IP Right Grant
- 2007-10-24 NO NO20075412A patent/NO20075412L/no not_active Application Discontinuation
-
2009
- 2009-09-29 US US12/569,552 patent/US8536118B2/en active Active
-
2012
- 2012-05-22 JP JP2012116934A patent/JP2012232979A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008535821A5 (enExample) | ||
| RU2007139452A (ru) | СПОСОБЫ И КОМПОЗИЦИИ ДЛЯ МОДУЛИРОВАНИЯ ГИПЕРСТАБИЛИЗИРОВАННОГО c-met | |
| Shah et al. | Expression of peroxisome proliferator-activated receptor-γ in macrophage suppresses experimentally induced colitis | |
| Jarad et al. | Albumin contributes to kidney disease progression in Alport syndrome | |
| WO2010005566A3 (en) | Notch-binding agents and antagonists and methods of use thereof | |
| UA105768C2 (uk) | Антитіла до рецептора кінцевих продуктів глибокого глікування (rage) і їх застосування | |
| Fu et al. | Signaling mechanism of renal fibrosis in unilateral ureteral obstructive kidney disease in ROCK1 knockout mice | |
| JP2007527865A5 (enExample) | ||
| MY192113A (en) | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment of anti-adm non-ig protein scaffold for reducing the risk of mortality in a patient having a chronic or acute disease or acute condition | |
| EP2119780A4 (en) | GENETICALLY RECOMBINANT ANTIBODY COMPOSITION WITH IMPROVED EFFECTOR ACTIVITY | |
| EA200970251A1 (ru) | Антитела к миостатину | |
| NZ596409A (en) | Anti macrophage migration inhibitory factor antibodies | |
| JP2014193892A5 (enExample) | ||
| JP2009531283A5 (enExample) | ||
| EA200970131A1 (ru) | Миметические антитела для glp-1 человека, композиции, способы и применения | |
| WO2008033395A3 (en) | Melanocortin and transferrin fusion proteins | |
| WO2006038027A3 (en) | SINGLE DOMAIN ANTIBODIES AGAINST TNFRl AND METHODS OF USE THEREFOR | |
| EA200801842A1 (ru) | Антитела против бета-амилоидного пептида | |
| JP2014508748A5 (enExample) | ||
| EA200700136A1 (ru) | Анти-cd154-антитела | |
| GT200600182A (es) | Anticuerpos dirigidos contra el peptido amiloide beta y metodo que utilizan los mismos | |
| WO2008019199A8 (en) | FCγRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF | |
| WO2009011941A3 (en) | Monoclonal antibodies against dengue and other viruses with deletion in fc region | |
| WO2012050874A2 (en) | Targeting heme for the treatment of immune mediated inflammatory diseases | |
| JP2011501652A5 (enExample) |